Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.

"Conflict of interest: G.M. Gauvreau reports grants and personal fees from AstraZeneca, and grants from Biohaven, Genentech and BioGaia, outside of the submitted work. J.M. Hohlfeld reports grants from Novartis AG, during the conduct of the study; grants from AltamiraPharma GmbH, Astellas Pharma GmbH, AstraZeneca AB, Bayer AG, Beiersdorf AG, Boehringer Ingelheim Pharma GmbH & Co. KG, CSL Behring GmbH, Desitin Arzneimittel GmbH, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline GmbH & Co. KG, Janssen Pharmaceuticals NV, M&P Pharma AG, Novartis AG, Sanofi-Aventis Deutschland GmbH and UCB Pharma GmbH and personal fees from Boehringer Ingelheim Pharma GmbH & Co. KG, CSL Behring GmbH, Merck & Co, Inc., Nocion Therapeutics, Inc., HAL Allergy Group and Novartis AG, outside of the submitted work. M.J. FitzGerald reported receipt of research funding from Novartis which was paid directly to UBC for the completion of this study and has also been in receipt of AllerGen CIHR and NIH grant funding unrelated to the current study. L-P. Boulet reports receiving grants from Amgen, AstraZeneca, GlaxoSmithKline, Merck, Novartis and Sanofi-Regeneron, personal fees from AstraZeneca, GlaxoSmithKline, Merck, Novartis and Sanofi-Regeneron, and honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events, outside of the submitted work. D.W. Cockcroft reports receiving grants from the Department of Medicine University of Saskatchewan, AstraZeneca, Novartis, CSACI and AllerGen NCE, outside of the submitted work. B.E. Davis has nothing to declare. S. Korn reports receiving personal fees from Novartis, outside of the submitted work. O. Kornmann reports receiving personal fees from Sanofi, Novartis, Boehringer Ingelheim, Adagio, AstraZeneca, Santhera and Chiesi, outside of the submitted work. R. Leigh reports receiving personal fees from Novartis, AstraZeneca, GlaxoSmithKline, Sanofi Genzyme and Valeo Pharma Inc., outside of the submitted work. I. Mayers has nothing to declare. H. Watz reports receiving grants and personal fees from Novartis, AstraZeneca, GlaxoSmithKline, Chiesi and Boehringer Ingelheim, outside of the submitted work. S.S. Grant, M. Jain and P.E. Pertel are employees of Novartis Institutes of Biomedical Research. M. Cabanski was an employee of Novartis during the time of the study. I. Jones and J.R. Lecot are employees of Novartis Pharma AG. H. Cao is an employee of Novartis Pharmaceuticals Corporation. P.M. O'Byrne has obtained grants in aid of research from Novartis for the conduct of the current study, as well as from AstraZeneca, Medimmune, Biohaven, Merck and Bayer for research outside the current study, and received personal fees for consulting or speaker fees from AstraZeneca, GSK, Medimmune, Chiesi, Menarini and Covis."

"The study was funded by Novartis Pharma AG (Basel, Switzerland). We thank the investigators, study staff and subjects at the investigative sites for their support during the conduct of the study. The authors also thank Hiral Joshi, Phani Tejasvi and Chiranjit Ghosh of Novartis Medical and Knowledge Solutions (Hyderabad, India) for providing medical writing support in accordance with Good Publication Practice guidelines. This manuscript is dedicated to the memory of Dr J. Mark FitzGerald. Support statement: The study was funded by Novartis Pharma AG (Basel, Switzerland) and AllerGen. The funders of the study participated in the study design and had access to the raw data. All authors, including those employed by the funders of the study, participated in the data collection, data analysis, data interpretation and writing of the report. The corresponding author had full access to all the data in the study and had final responsibility to submit for publication. Funding information for this article has been deposited with the Crossref Funder Registry."

"This study is registered at ClinicalTrials.gov with identifier number NCT03138811. Data sharing: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymised to respect the privacy of subjects who have participated in the trial in line with applicable laws and regulations. Result summaries have been posted on the Novartis clinical trial database and other online public databases. More information on Novartis’ position on access to clinical trial results and patient-level data is available at: www.novartis.com/our-science/clinical-trials/clinical-trial-information-disclosure"